Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis

   Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss.

   Latona has also entered into a purchase and sale agreement to acquire the Orphan Drug Status, clinical data set and trademark to Oralgam with Protein Therapeutics Inc. of Tucson, Arizona. Under the terms of this agreement Latona will acquire the Orphan Drug Status to Oralgam for the treatment of Juvenile Rheumatoid Arthritis, GI Dysfunction in Autism and Dermatomyostis.

   "Latona is extremely pleased to acquire the worldwide rights to Oralgam," stated Joseph Koziak, CEO of Latona. "We believe that Oralgam has the potential to provide significant relief to those who suffer from Arthritis and potential other auto-immune disorders."

   Keywords: Arthritis, Audiology, Business, Drug Development, Hearing Loss, Marketing and Licensing Agreements, Otolaryngology, Patents Actions, Pharmaceuticals, Rheumatoid Arthritis, Therapy, Treatment, Latona Life Sciences Inc.

   This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2008, Pain & Central Nervous System Week via NewsRx.com.

Return to Medical Patents Alert Section